What is CDNF? Conserved Dopamine Neurotrophic Factor Growth factor known as a trophic factor Stimulates the growth of neurons.

Slides:



Advertisements
Similar presentations
Louis Carney III BME 281 October 8 th,  About 300,000 Americans a year suffer damage to peripheral and central nerves.  Nerves damaged in the.
Advertisements

Parkinson's Disease Animal Models and Possible Treatments.
Kelsie Chasan Gianni Grasso.  7-10 million diagnosed  60,000 diagnosed each year  Majority over 50 years old  Men more likely.
Making Every Little Bit Count: Parkinson’s Disease SHP – Neurobiology of Development and Disease.
The Application of the Scientific Method: Preclinical Trials Copyright PEER.tamu.edu.
Andrea Janeš Mentor: A. Žmegač Horvat
B 尤思涵. Dopamine and Serotonin Dopamine 4-(2-aminoethyl)benzene-1,2-diol 5-Hydroxytryptamine or 3-(2-aminoethyl)-1H-indol-5-ol Serotonin.
AMPAKINE Compounds for the Treatment of Rett Syndrome
What are they and what can we do with them?
Monday 20 th July 2009 Parkinson’s Summerschool A Personal Perspective On Parkinson’s Tom Isaacs Co-Founder – Cure Parkinson’s Trust Board Member – European.
Subthalamic GAD Gene Therapy in a Parkinson’s Disease Rat Model
VIRUSES Tobacco mosaic virus Influenza virus Adenovirus Bacteriophage.
ANALYZING THE NEUROPROTECTIVE POTENTIAL OF NICOTINE IN PARKINSON’S DISEASE (PD) AND ITS EFFECT ON DOPAMINE LEVELS IN RODENTS AND PRIMATES Lucas Buffone,
Parkinson’s Disease storyboard. Possible Intro Scenario As an resident at Normal Hospital, you are beginning your rotation in neurology. Your supervisor,
Separating Storage from Retrieval Dysfunction of Temporal Memory in Parkinson’s Disease Chara Malapani, Bernard Deweer, John Gibbon Presented by: Vincent.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Intranasal Delivery of Proteins Using Cationic Liposomes for the Treatment of Parkinson’s Disease and the Use of Bioquant ® Image Analysis Software Presented.
AAV2-NRTN (CERE-120) In Parkinson’s Disease: Phase 2 Trial Results and Path Forward Joao Siffert, MD Chief Medical Officer Ceregene, Inc. San Diego, CA.
Motor Response Complications and Cycline-Dependent Kinase 5 (Cdk5) Neuroadaptations in an Animal Model of Parkinson’s Disease Heather Minkel Dr. Justin.
Salvador Dali (Painter) Mao Zedong (Chinese Politician) Michael J Fox (Actor) Pope John Paul II Muhammad Ali (Boxer) Janet Reno (Former AG)
DOPAMINE HYPOTHESIS.
Regulating the Cell Cycle Controls on Cell Division If we look at cells dividing in a petri dish we can see that they will divide until they cover.
PARKINSON’S DISEASE BY: NICOLE MABARDI & SHAINA JOSEPH.
Knowledge Engineering Start with the question: “What is an ‘atom’ of scientific knowledge?”
How are medicines developed?. What is it? What’s inside?
Senior lecturer, Department of Biotechnology, Tel-Hai academic collage, Israel & Oxidative Stress and Human Diseases Research Laboratory – Galilee Research.
Biological Explanations for Schizophrenia
Separating Storage from Retrieval Dysfunction of Temporal Memory in Parkinson’s Disease Malapani, Deweer & Gibbon (2002) Tiffany Wang.
Using Stem Cells to Treat Ailments of the Nervous System Crista Chavez, Jacqueline Doody, Nina Roxo, Aleksandra Sabov & Zachary Taylor Faculty Mentor:
TRAUMATIC BRAIN INJURY Traumatic Brain Injury (TBI) is an injury where a person hits their head on object,resulting in serious brain damage. TBI is often.
Pathogenesis and pathology of parkinsonism
Learning. What is Learning? Acquisition of new knowledge, behavior, skills, values, preferences or understanding.
Parkinson’s Disease Casey Wang
Worldwide, 1.6 million new cases of breast cancer are diagnosed each year, leading to over half a million deaths. 40 years ago in the UK, the five-year.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pharmacological Treatment of Parkinson Disease: A.
How Do Drugs Affect Synapses? BY RUI XIAO. Psychoactive Drugs  Psychoactive drugs are chemical substances that can alter brain functions and result in.
Reflections on animal models of neurological disorders Marie-Francoise Chesselet UCLA
Dr. Diala Abu-Hassan, DDS, PhD Central Nervous System Dr. Diala Abu-Hassan School of Medicine 1
Plenary Session: An update of brain circuits in Parkinson’s and Deep Brain Stimulation
By the end of this section you will be able to …..
CD4+ T-lymphocyte count <100 cells/µl
Falon Fiorillo & Breeanna Fournier
The Effects of 6-hydroxydopamine (6-OHDA) and Neuronal Nitric Oxide Synthase Inhibitor ( nNOSI) on Ability of Zebrafish to recover from parkinson’s disease-like.
Nitric Oxide (NO) and How it Regulates Motor Function
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
or multiple system atrophy (MSA)
Volume 16, Issue 3, Pages (March 1996)
Control of Gene Expression
Regulation of Presynaptic Neurotransmission by Macroautophagy
DNA and the Genome Key Area 4b Stem Cells.
Copyright © 2004 American Medical Association. All rights reserved.
Julius A. Steinbeck, Lorenz Studer  Neuron 
Roger A. Barker, Malin Parmar, Lorenz Studer, Jun Takahashi 
Q: How can we prevent or treat Alzheimer’s Disease?
Volume 60, Issue 2, Pages (October 2008)
Volume 11, Issue 1, Pages (July 2018)
Andrea Maddalena, Julia Tereshchenko, Mathias Bähr, Sebastian Kügler 
Roger A. Barker, Malin Parmar, Lorenz Studer, Jun Takahashi 
Volume 24, Issue 5, Pages (May 2016)
Losartan pretreatment reduces neurodegeneration and behavioural symptoms in 6- hydroxydopamine induced unilateral rat model of Parkinson's disease  Ali.
Raymond T Bartus, Marc S Weinberg, R. Jude Samulski  Molecular Therapy 
Volume 15, Issue 1, Pages (January 2007)
Volume 6, Issue 4, Pages (April 2016)
Coregulation of VGAT and cGMP levels by dopamine.
The Blood-Brain Barrier
Network-Level Changes in Expression of Inducible Fos–Jun Proteins in the Striatum during Chronic Cocaine Treatment and Withdrawal  Rosario Moratalla,
Activity-dependent suppression of the proapoptotic gene Puma protects neurons. Activity-dependent suppression of the proapoptotic gene Puma protects neurons.
Section 4 Lesson 6 – Gene Therapy
Conceptual diagram of dopaminergic system and disease and drug effects
Presentation transcript:

What is CDNF? Conserved Dopamine Neurotrophic Factor Growth factor known as a trophic factor Stimulates the growth of neurons

Recent In Vivo Studies Scientists need rats that exhibit Parkinson’s- like symptoms – Administer 6-Hydroxydopamine (6-OHDA) Kills off Dopaminergic neurons Induces Parkinson’s-like symptoms L-DopaDopamine 6-hydroxydopamine

Important Lab Findings CDNF was injected into Striatum of rats before 6-OHDA – CDNF prevented PD symptoms from occurring Rats were treated to express PD symptoms – Injected with 6-OHDA – 4 weeks later, treated with CDNF Neuron function and viability was restored

Screening Patients Adequate patient response to L-Dopa – Indicates DA neurons are degraded but treatable No effect of L-Dopa – Indicates that DA neurons have degraded completely

Benefits in human trials CDNF has a “protective” effect – Prevents neuron degradation CDNF can restore up to 98% function – Promoting DNA replication Can be administered through lumbar puncture – Out-patient procedure – Anaesthetized for comfort – Use Mannitol to penetrate the Blood-Brain-Barrier